 |
Indication & Dosage |
| |
| |
| Oral |
| MALIGNANCIES |
| Adult:
Treatment of chronic myeloid leukaemia: 20-30 mg/kg/day in single doses. Treatment of solid tumours: Single doses of 80 mg/kg every 3rd day. If used with radiotherapy, treatment should be started 7 days before initiation of radiotherapy. |
| |
| Oral |
| SICKLE-CELL DISEASE |
| Adult:
Initially, 15 mg/kg daily, increased by 5 mg/kg/day every 12 wk according to response and blood counts. Max: 35 mg/kg daily. |
| |
| Oral |
| SICKLE-CELL DISEASE |
| Child:
1-18 yr: 10-20 mg/kg daily, increased by 5 mg/kg/day every 12 wk according to response and blood counts. |
| |
| Oral |
| ESSENTIAL THROMBOCYTHAEMIA |
| Adult:
15 mg/kg daily. Adjust subsequent doses based on platelet counts. |
|
| |
|
| Precautions |
Regular monitoring of uric acid concentrations, blood counts, renal and hepatic function is recommended. Prior irradiation therapy. Elderly. Avoid use of live vaccines. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
GI disturbances, renal impairment, pulmonary oedema, dermatological reactions, headache, dizziness. Disorientation, drowsiness, hallucinations, convulsions, alopecia. |
| |
|
| Adverse Drug Reactions |
Bone marrow suppression. |
| |
|
| Interactions |
Impairs immune response to vaccines; possible infection with live vaccines, zidovudine, zalcitabine. May alter action of oral anticoagulants and phenytoin. |
| |
|
|
|
